Similar companies
Income Statement (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Operating expense | 2M | 39.6% |
| Net Income | -2.2M | 33.8% |
| EBITDA | -2M | 39.3% |
Balance Sheet (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Total Assets | 3.9M | 162.8% |
| Total Liabilities | 3.7M | 121.5% |
| Total Equity | 140,000 | 165% |
| Shares Outstanding | 18M | 44.9% |
Cash Flow (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Cash from operations | -2.1M | 4.6% |
| Cash from financing | 4.7M | 1889.6% |
EPS
Financial Highlights for Oragenics in Q1 '25
Operating Expenses for this period were 2M, showing a -39.6% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -2.2M, showing a 33.8% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -2M, showing a 39.3% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
The company's performance remained stable this quarter with no significant positive or negative changes in the key financial metrics.
